MS Variance: Empowered patients and the role of self-directed care

3 December, 2018 | Posted in:

During the course of the two day MS Variance event, participants heard about the importance of engaging, involving, and empowering people living with MS as a key piece to ending service variation. A core view expressed during various presentations both by professionals involved in healthcare, people living with MS, and those with experience of both, […]

Continue Reading »

MS Variance: Monitoring DMTs and the costs associated with good care

30 November, 2018 | Posted in:

At the MS Variance meeting, Rachel Dorsey-Campbell, neuroscience pharmacist at the Imperial NHS Trust, presented her team’s latest research project examining the real cost of effective and safe monitoring for disease-modifying treatments (DMTs). Rachel, graduate of the MS MasterClass, winner of the MS 3 MasterClass Project Award 2018 and one of eight pharmacists in attendance […]

Continue Reading »

MS Variance: The NHSE DMT Algorithm and the challenges it poses

26 November, 2018 | Posted in:

The driving force behind the MS Variance meeting came from another event the Neurology Academy hosted earlier this year: the debate over the pros and cons of the new NHS England MS algorithm for disease-modifying treatments (DMTs). That one algorithm meeting threw up a whole array of discussion points, and we heard viewpoints across health […]

Continue Reading »

MS service variance – the way forward

15 October, 2018 | Posted in:

Access to services for people with multiple sclerosis (MS) is well known to be varied, with phrases like ‘postcode lottery’ and ‘patchy’ commonly used to describe people’s access to the care and support that they need. Anecdotally known of for some time, recent evidence now highlights not just the variation, but the impact it has […]

Continue Reading »

MS community fight for new drug to treat primary-progressive MS

14 September, 2018 | Posted in:

New disease-modifying drug Ocrelizumab could be the treatment that many people with primary-progressive MS have been waiting for, but despite positive clinical outcomes, it has yet to be licensed here in the UK. Multiple sclerosis (MS) causes inflammation of the nerve cells in the brain and spine, and disease-modifying therapies (DMTs) are a form of […]

Continue Reading »

Autumn 2018 MS MasterClass project winners announced

7 September, 2018 | Posted in:

Congratulations are thoroughly deserved by our latest MS MasterClass project winners. The most recent cohort of delegates to complete their intermodule projects met last night at their Awards dinner during this Autumn MasterClass course. MS specialist nurse Daisy Cam won the Project Award for her research into the use of alternative therapies in treating MS. […]

Continue Reading »

Technology advances in neurology healthcare

31 August, 2018 | Posted in:

We live in a technological era and seldom a moment goes by when we are not using some sort of device or app, browsing the internet or relating across social media. Healthcare has long seemed behind in using these advances in technology to improve their services, but this is beginning to change. Exciting headway From […]

Continue Reading »